Author:
Cucherat Michel,Laporte Silvy,Delaitre Olivier,Behier Jehan-Michel,d’Andon Anne,Binlich Florence,Bureau Serge,Cornu Catherine,Fouret Cécile,Hoog Labouret Natalie,Laviolle Bruno,Miadi-Fargier Houda,Paoletti Xavier,Roustit Matthieu,Simon Tabassome,Varoqueaux Nathalie,Vicaut Eric,Westerloppe Jérémie
Reference19 articles.
1. A review of NICE appraisals of pharmaceuticals 2000–2016 found variation in establishing comparative clinical effectiveness;Anderson;J Clin Epidemiol,2019
2. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial;Spiera;Ann Rheum Dis,2011
3. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial;Prey;Br J Dermatol,2012
4. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial;Khanna;Lancet,2016
5. Rare diseases: natural history studies for drug development. Guidance for industry;Food and Drug Administration,2019
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献